Hospitals report these codes with terse, inconsistent chargemaster text. This plain-English title was written by an AI model from that text and has not been reviewed by a person, so it can be wrong. The prices on this page come straight from hospital filings and do not depend on it.
Original text from hospital filings
LISOCABTAGENE MARALEUCEL, UP TO 110 MILLION AUTOLOGOUS ANTI-CD19 CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE
Omaha, NE
See all hospitals reporting HCPCS Q2054 →Price type
Nebraska Medical Center’s median price of $3459k is 485% above the median hospital's median price ($591.2k), higher than 100% of the 1,128 hospitals reporting HCPCS Q2054. The highlighted bar is where this hospital falls; shaded is the middle 50% of hospitals.
Last updated: Aug 10, 2026
See Lisocabtagene maraleucel CAR-T cell therapy dose pricing across every hospital in the network reporting it, or ask Claude or any MCP client directly — see how to connect.